Integrated proteomic and metabolomic profiling of urine of renal anemia patients uncovers the molecular mechanisms of roxadustat-Reference-Cited by-同舟云学术

Integrated proteomic and metabolomic profiling of urine of renal anemia patients uncovers the molecular mechanisms of roxadustat

Published:2023 Issue:6 Volume:19 Page:473-483
ISSN:2515-4184
Container-title:Molecular Omics
language:en
Short-container-title:Mol. Omics

Author:

You Xiaoe¹^ORCID,Guo Baochun¹²³,Wang Zhen¹²³,Ma Hualin¹²³,Liu Lixia¹²³,Zhou Ru¹²³,Zheng Yaxuan¹,Zhang Xinzhou¹²³

Affiliation:

1. The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen 518020, Guangdong, China

2. Department of Nephrology, Shenzhen Peoples Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, Guangdong, China

3. Shenzhen Key Laboratory of Kidney Diseases, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518055, Guangdong, China

Abstract

Roxadustat (FG-4592) is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) prescribed to patients with low hemoglobin associated with chronic kidney disease.

Publisher

Royal Society of Chemistry (RSC)

Subject

Genetics,Molecular Biology,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/MO/D3MO00015J

Reference38 articles.

1. Roxadustat: First Global Approval

2. A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat

3. The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis

4. Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2016–2020)

5. The prolyl hydroxylase inhibitor roxadustat: Paradigm in drug discovery and prospects for clinical application beyond anemia